Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1
Authors:
Open Access
- 1 February 2007
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 56 (2) , 438-443
Abstract
Glucagon-like peptide (GLP)-1 mimetics have been reported to cause hypoglycemia when combined with sulfonylureas. This study investigated the impact of tolbutamide on the glucose dependence of the GLP-1–mediated effects on insulin, glucagon, and somatostatin secretion in the in situ perfused rat pancreas. At 3 mmol/l glucose, GLP-1 alone did not augment insulin secretion, whereas tolbutamide alone caused a rapid increase in insulin secretion. However, when GLP-1 and tolbutamide were administered simultaneously, insulin secretion increased significantly to 43.7 ± 6.2 pmol/min (means ± SE), exceeding the sum of the responses to GLP-1 (2.0 ± 0.6 pmol/min; P = 0.019) and tolbutamide (11.3 ± 3.8; P = 0.005) alone by a factor of 3.3. At 11 mmol/l glucose, co-infusion of GLP-1 and tolbutamide augmented insulin secretion to 141.7 ± 10.3 vs. 115.36 ± 14.1 (GLP-1) and 42.5 ± 7.3 pmol/min (tolbutamide). Interestingly, increases in somatostatin secretion, both by glucose and GLP-1, were consistently paralleled by suppression of glucagon release. In conclusion, we demonstrate uncoupling of GLP-1 from its glucose dependence by tolbutamide. This uncoupling probably explains the tendency of GLP-1 to provoke hypoglycemia in combination with sulfonylureas. The results suggest that closure of ATP-sensitive K+ channels by glucose might be involved in the glucose dependence of GLP-1’s insulinotropic effect and that somatostatin acts as a paracrine regulator of glucagon release.Keywords
This publication has 52 references indexed in Scilit:
- New Insights Concerning the Glucose-dependent Insulin Secretagogue Action of Glucagon-like Peptide-1 in Pancreatic β-CellsHormone and Metabolic Research, 2005
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1Diabetes/Metabolism Research and Reviews, 2002
- Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy VolunteersThe Journal of Clinical Endocrinology & Metabolism, 2002
- Characterisation of sulphonylurea and ATP-regulated K + channels in rat pancreatic A-cells1999
- Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat PancreasDiabetes Care, 1996
- cAMP-signaling pathway acts in selective synergism with glucose or tolbutamide to increase cytosolic Ca2+ in rat pancreatic beta-cellsDiabetes, 1996
- Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)Nature, 1993
- Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.Journal of Clinical Investigation, 1991
- Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide.Journal of Clinical Investigation, 1977